Oxazolidinones as novel human CCR8 antagonists

  • Bioorg Med Chem Lett. 2007 Mar 15;17(6):1722-5. doi: 10.1016/j.bmcl.2006.12.076.
Jian Jin  1 ,  Yonghui Wang ,  Feng Wang ,  Jeffery K Kerns ,  Victoria M Vinader ,  Ashley P Hancock ,  Matthew J Lindon ,  Graeme I Stevenson ,  Dwight M Morrow ,  Parvathi Rao ,  Cuc Nguyen ,  Victoria J Barrett ,  Chris Browning ,  Guido Hartmann ,  David P Andrew ,  Henry M Sarau ,  James J Foley ,  Anthony J Jurewicz ,  James A Fornwald ,  Andy J Harker ,  Michael L Moore ,  Ralph A Rivero ,  Kristen E Belmonte ,  Helen E Connor
Affiliations
  • 1. Discovery Medicinal Chemistry, Molecular Discovery Research, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA. [email protected]
PMID: 17267215 DOI: 10.1016/j.bmcl.2006.12.076
Abstract

High-throughput screening of the corporate compound collection led to the discovery of a novel series of N-substituted-5-aryl-oxazolidinones as potent human CCR8 antagonists. The synthesis, structure-activity relationships, and optimization of the series that led to the identification of SB-649701 (1a), are described.

Products